On April 2, 2020, Horizon Therapeutics announced that it has acquired Curzion Pharmaceuticals, a privately owned biopharma company, and its development-stage oral selective lysophosphatidic acid 1 receptor (LPAR1) antagonist, CZN001 (renamed HZN-825).

Under the terms of the agreement, Horizon acquired Curzion for a $45 million upfront cash payment with additional payments contingent on the achievement of development and regulatory milestones. CZN001 was originally discovered and developed by Sanofi.

A Wilson Sonsini Goodrich & Rosati team representing Curzion on company patent matters and on IP matters related to the acquisition includes Michael Hostetler and Valentin Zunic.